Introduction
The Organ-on-chip Market size is estimated at USD 0.39 billion in 2025, and is expected to reach USD 1.51 billion by 2030, at a CAGR of 30.94% during the forecast period (2025-2030). This growth reflects increasing adoption of microphysiological systems in drug discovery, toxicology screening and disease modelling. The market share of organs-on-chips is rising as pharmaceutical and biotechnology companies seek alternatives to animal testing, and contract research organisations (CROs) expand services in this domain. The organs-on-chips market analysis points to robust growth in regions such as Asia-Pacific and North America, as well as emerging opportunities across organ types, applications and end-users.
Key Trends in the Organs-on-Chips Market
Regulatory Shift Toward Animal-Free Preclinical Testing
A major driver of the organs-on-chips market is the accelerating shift toward animal-free preclinical testing mandates. Regulatory frameworks in several regions increasingly accept chip-based, human-relevant microphysiological models as alternatives to animal studies. This trend is expanding the adoption of microfluidic organ-on-chip platforms and reshaping traditional preclinical workflows.
Rising Burden of Chronic and Complex Diseases
The growing global incidence of chronic and complex diseases is heightening the need for physiologically relevant in-vitro models. Organs-on-chips that mimic human disease conditions are gaining traction because they improve predictability of therapeutic outcomes and reduce late-stage clinical attrition. These factors significantly reinforce the organs-on-chips market trends.
Growth of Precision Medicine and Patient-Derived Chips
Advances in precision medicine are driving the adoption of patient-derived organ-on-chip models. These platforms allow developers to test therapies tailored to an individual’s biology, enhancing the relevance of experimental outcomes and supporting clinical translation. This trend is becoming a major contributor to organs-on-chips market growth.
Rising Need for Early Drug-Toxicity Detection
Demand for early detection of drug toxicity is increasing, supported by new product launches in the organs-on-chips landscape. Integration of these systems into drug discovery workflows is rising as researchers prioritize endpoints such as liver toxicity, kidney-clearance dynamics, and multi-organ interaction. This is improving the efficiency and safety of therapeutic development.
Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights:
https://www.mordorintelligence.com/ja/industry-reports/organs-on-chips-market?utm_source=emailwire
Market Segmentation of the Organs-on-Chips Market
The organs-on-chips market segmentation is structured across organ type, application and end-user groups, as follows:
By Organ Type
- Liver
- Heart
- Lung
- Kidney
- Intestine
- Brain & CNS
- Skin
- Multi-Organ & Other Complex Systems
By Application
- Drug Discovery & Lead Identification
- ADME/Toxicology Screening
- Disease Modeling
- Precision Medicine & Personalized Therapy
- Other Applications
By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic & Research Institutes
- Cosmetics & Personal Care Industry
- Other End Users
By Geography
- North America
- South America
- Europe
- Middle east&Africa
- Asia pacific
Key Players in the Organs-on-Chips Market
The organs-on-chips market features a moderately fragmented competitive landscape with numerous vendors pursuing platforms, consumables and services. Several of the major players include Emulate Inc., MIMETAS BV, CN Bio Innovations, Hesperos Inc. and Altis Biosystems.
- BiomimX SRL
- Elveflow
- Emulate Inc.
- Altis Biosystems
- AxoSim
Conclusion
The organs-on-chips market is poised for meaningful growth as the market size expands from around USD 0.39 billion in 2025 to approximately USD 1.51 billion by 2030. This trajectory reflects increasing adoption of physiologically relevant microfluidic models across drug discovery, toxicology, and disease modelling. The organs-on-chips market share is being shaped by organ-type diversification (notably lung and heart), application focus (especially drug discovery and disease modelling), and end-user expansion (with CROs growing fast). Key trends such as animal-testing replacement mandates, precision-medicine demand, and microfabrication advances are supporting the organs-on-chips market growth. At the same time, challenges like technical complexity, high costs and regulatory hurdles remain. As vendors innovate and collaborations deepen, stakeholders in the organs-on-chips market are well positioned to capitalise on an evolving research-tool ecosystem. For companies, researchers and investors alike, understanding the organs-on-chips market analysis is essential to navigate this dynamic landscape and seize upcoming opportunities.
Industry related Reports:
France Artificial Organs & Bionics Market: The French Artificial Organs and Bionics Market is segmented by type into artificial organs including artificial heart, artificial kidney, cochlear implants, and other organ types and bionics, which comprise vision bionics, ear bionics, orthopedic bionics, and cardiac bionics. The report provides market values in USD million for all these segments, offering a detailed view of the country’s growing adoption of advanced organ-replacement and bionic technologies.
Organoids Market: The Organoids Market is segmented by type into stem-cell-derived and tumor-derived organoids, by application covering drug discovery and screening, disease and toxicology modeling, and other emerging uses, and by end users that include pharmaceutical and biotech companies as well as academic and research institutes. It is further categorized by technology, such as scaffold-based 3D culture and additional advanced platforms, and analyzed across key regions including North America and others, with market forecasts presented in terms of value (USD).
Primary Cell Culture Market: The Primary Cell Culture Market is segmented by product type (including primary cells and other related products), cell type (animal and human cells), separation method (such as enzymatic disaggregation and others), culture platform (2D monolayer culture and additional advanced platforms), and applications (including vaccine production and other uses). It also categorizes end users such as diagnostic laboratories and others, with geographical coverage spanning North America and additional global regions, with all market forecasts presented in terms of value (USD).
About Mordor Intelligence:
Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.
With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.
For any inquiries or to access the full report, please contact:
media@mordorintelligence.com
https://www.mordorintelligence.com/
